Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Xalatan

Xalatan
In stock
2,5ml
from 73,39 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
88,07 £73,39 £
73,39 £ per bottle

In brief

  • In our pharmacy, you can buy Xalatan without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
  • Xalatan (active ingredient latanoprost) is used to lower raised intraocular pressure in open‑angle glaucoma and ocular hypertension; it is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humour.
  • The usual dose is 1 drop of 0.005% (0.05 mg/mL) in the affected eye once daily in the evening; dosing more frequently does not increase efficacy.
  • The form of administration is topical ophthalmic solution (eye drops) supplied as multidose dropper vials (2.5 mL, 5 mL) or preservative‑free single‑dose containers.
  • The effect begins within about 3–4 hours after instillation, with peak intraocular pressure reduction typically seen at 8–12 hours.
  • The duration of action is approximately 24 hours, which allows once‑daily dosing and long‑term chronic use while pressure control is required.
  • Alcohol warning: no specific interaction with alcohol is known and moderate alcohol consumption is unlikely to affect the drops, but avoid excessive alcohol that may worsen dry eyes and consult a clinician if you have concerns.
  • The most common side effects are increased iris pigmentation (darkening of the coloured part of the eye), eyelash growth and periocular skin darkening; other common effects include conjunctival hyperaemia, eye irritation, blurred vision and foreign‑body sensation.
  • Would you like to try Xalatan without a prescription?

Basic Xalatan information

  • INN (international nonproprietary name): Latanoprost
  • Brand names available in the United Kingdom: Xalatan; Monoprost (preservative‑free); generic latanoprost.
  • ATC code: S01EE01 (S01 = ophthalmologicals; EE = prostaglandin analogues; 01 = latanoprost)
  • Forms and dosages: 0.005% (0.05 mg/mL) topical ophthalmic solution in multidose dropper vials (typically 2.5 mL or 5 mL) and preservative‑free single‑dose containers.
  • Manufacturers in the United Kingdom: Viatris (Xalatan), Théa (Monoprost) and generic manufacturers such as Glenmark and Sun Pharma.
  • Registration status in the United Kingdom: Latanoprost products such as Xalatan and Monoprost are licensed by the MHRA and available on prescription in the UK.
  • OTC / Rx classification: Prescription-only medicine (POM).

Critical warnings and restrictions

Who should be careful? Patients often ask if latanoprost is safe for them, especially if they are elderly, pregnant or have chronic disease.

Prioritise safety: latanoprost is prescription‑only and must be started and reviewed by an ophthalmologist or GP with shared‑care arrangements on the NHS.

  • Absolute contraindications: Known hypersensitivity to latanoprost or any excipient.
  • Absolute contraindications: History of herpetic keratitis — specialist review required.

Relative risks require clinical judgement and monitoring.

  • Relative contraindications/monitoring: Active intraocular inflammation such as uveitis.
  • Relative contraindications/monitoring: Aphakia or pseudophakia with a torn posterior capsule (increased macular oedema risk).
  • Relative contraindications/monitoring: Severe asthma — inform prescribers of respiratory disease as rare bronchospasm has been reported.

High-risk groups

  • Elderly: No routine dose adjustment generally required, but monitor ocular surface changes, tolerance and adherence.
  • Pregnancy and breastfeeding: Avoid unless a specialist advises that benefit outweighs risk; prostaglandin analogues are used only when necessary.
  • Chronic illness: Patients with active ocular inflammation, recent ocular surgery or unstable systemic respiratory disease need specialist input.

Interaction with activities

  • Instillation can cause transient stinging, tearing or blurred vision and may impair driving or operation of machinery until vision clears.
  • Report any ocular irritation that affects workplace precision tasks to the employer where required under UK safety rules.
  • Pharmacists should counsel patients to avoid immediate driving after drops until comfortable and to report suspected adverse reactions via the Yellow Card scheme.

Q&A — Can I drive after taking it in the UK?

If drops cause transient blurred vision or stinging, wait until vision has cleared before driving.

Do not drive if vision is affected; inform your prescriber if problems persist.

Usage basics

INN, brand names available in the UK

INN: latanoprost is the active ingredient in Xalatan and in multiple generics distributed in the UK.

UK brand examples include Xalatan and Monoprost, with preservative‑free options such as Monoprost single‑dose containers.

Legal classification (POM, P, GSL)

Latanoprost is classified as a prescription-only medicine (POM) for glaucoma and ocular hypertension in the UK.

The MHRA oversees product licensing and labelling.

  • INN: International Nonproprietary Name — Latanoprost.
  • Brand: Trade or proprietary name — for example Xalatan, Monoprost.
  • Dosage form: Ophthalmic solution 0.005% in multidose or single‑dose containers.
  • POM: Prescription-only medicine — requires a valid prescription.
Packaging type Practical difference
Multidose (2.5 mL, 5 mL) Contains preservative in many formulations; suitable for long‑term use if tolerated.
Single‑dose preservative‑free Better for ocular surface disease or contact lens users.

Dosing guide

Standard regimens (NHS guidelines)

Typical dose is one drop of latanoprost 0.005% in the affected eye or eyes once daily, preferably in the evening.

Dosing more frequently does not improve effect and may reduce IOP‑lowering efficacy.

Therapy is chronic and continues while intraocular pressure control is required with regular IOP checks.

Adjustments for comorbidities

  • Children: limited data; consult a paediatric glaucoma specialist for off‑label use.
  • Elderly: no routine dose adjustment but monitor ocular surface and adherence.
  • Liver/kidney impairment: no formal adjustment, use with caution as systemic studies are limited.

Q&A — What if I miss a dose?

If you miss a dose, give it as soon as you remember on the same day.

If it is almost time for your next dose, skip the missed dose — do not double up.

  • Evening dosing routine: Instil one drop once each evening at a consistent time to aid adherence.
  • Monitoring schedule: Baseline IOP and optic nerve assessment, early review at 4–6 weeks, then 3–12 monthly depending on stability.

Interaction chart

Food and drinks

Latanoprost is applied to the eye and has low systemic absorption, so no clinically significant interactions with alcohol or caffeine are documented.

Avoid using contact lenses during instillation and wait 15 minutes before reinserting lenses.

Avoid ocular cosmetics immediately around the lid margin during treatment to reduce residue trapping.

Common drug conflicts

Interaction type Practical advice Source/action
Contact lenses Remove lenses before administration; wait ≥15 minutes to reinsert Manufacturer guidance / product labelling
Other topical eye medicines Space different drops by ≥5 minutes to avoid washout and improve tolerability Clinical practice guidance
Systemic prostaglandin therapies Systemic interactions unlikely due to low absorption; monitor if unusual symptoms occur MHRA vigilance
  • Immediate precautions: do not share bottles, avoid contaminating tip, and report worsening redness or respiratory symptoms.
  • Report suspected adverse reactions through the MHRA Yellow Card via a pharmacist or the MHRA website.

Legal status and availability in the UK

In our online pharmacy, Xalatan is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism and pharmacology

Simplified explanation

Latanoprost is a prostaglandin F2α analogue that increases uveoscleral outflow of aqueous humour, lowering intraocular pressure.

Applied topically, it is absorbed into ocular tissues with minimal systemic exposure.

Clinical terms

  • Uveoscleral outflow: Alternate pathway for aqueous humour drainage that latanoprost enhances.
  • IOP: Intraocular pressure — the target for glaucoma treatment.
  • Prostaglandin analogue: Drug class to which latanoprost belongs.
  • Onset: IOP reduction begins within hours to days; maximal effect often after several weeks of continuous dosing.
  • Monitoring: regular IOP checks and optic nerve assessment to ensure target pressure is achieved.

Indications and off-label uses

MHRA‑approved uses

Licensed indication is treatment of open‑angle glaucoma and ocular hypertension to lower intraocular pressure.

Off‑label practices in NHS and private care

  • Paediatric glaucoma: limited, specialist‑led off‑label use under consultant care with informed consent.
  • Preservative‑free use: selected for patients with ocular surface disease even when licensed formulations are tolerated poorly.
  • Formulary switching: switching between branded and generic latanoprost is common; counsel patients about potential cosmetic or tolerability differences.
  • Clinician responsibilities when prescribing off‑label: document rationale, obtain informed consent, arrange close monitoring.

Alternatives matrix

NHS prescribing alternatives

Drug Class Typical effects Preservative status Pros / cons
Bimatoprost (Lumigan) Prostaglandin analogue IOP reduction similar; notable eyelash changes Varies by product May cause greater eyelash growth; useful alternative if latanoprost intolerance
Travoprost (Travatan) Prostaglandin analogue Comparable IOP lowering Some preservative‑free options Good alternative; choice guided by tolerance and formulary
Tafluprost (Saflutan) Prostaglandin analogue IOP lowering with preservative‑free options Preservative‑free available Useful for ocular surface disease
Topical beta‑blockers Beta‑blocker Effective IOP lowering but systemic effects Varies Not suitable for severe asthma; consider comorbidities

Pros and cons checklist

  • Switching therapies: consider efficacy parity, side‑effect profiles, ocular surface and patient preference.
  • Formulary choices often determine first choice on the NHS; discuss cosmetic effects with patients before switching.
  • For patients with asthma or respiratory disease, avoid topical beta‑blockers where possible and favour prostaglandin analogues.

Common questions

  • Will latanoprost change my eye colour?
  • Answer: A gradual increase in iris pigmentation can occur, especially in mixed or heterochromic irides, and may be permanent in the treated eye.
  • Can I wear contact lenses?
  • Answer: Remove soft contact lenses before instillation and wait at least 15 minutes before reinsertion; preservative‑free single‑dose formats may be more comfortable.
  • How soon will I notice benefit?
  • Answer: IOP reduction begins within hours to days, with maximal effect after several weeks; regular monitoring determines treatment success.
  • How do I report side effects?
  • Answer: Contact your prescriber or pharmacist and consider MHRA Yellow Card reporting for suspected adverse reactions.
  • Urgent advice checklist: seek immediate care for severe eye pain, sudden vision loss, increasing redness with discharge, or signs of macular oedema in pseudophakic/aphakic patients.

Registration and regulation

MHRA approval process

The MHRA oversees UK licensing and pharmacovigilance and many latanoprost products hold UK marketing authorisations.

Prescribers should follow licensed indications and local trust formularies when selecting branded or generic products.

NHS prescribing framework

Latanoprost is a POM and repeat dispensing or shared‑care agreements are common in chronic glaucoma management with scheduled ophthalmology reviews.

  • Prescribers: confirm licence status, document counselling and schedule follow‑up IOP checks.

Storage and handling

UK household storage (cold / damp climate)

Store unopened bottles refrigerated at 2–8°C when the product labelling specifies refrigeration before opening.

After opening, store at room temperature below 25°C, protect from light and discard after the manufacturer‑specified period, commonly 4–6 weeks.

In UK homes prone to damp or variable temperatures, keep vials in their original box and away from radiators and sunlight.

Guidance from NHS and pharmacists

  • At‑home storage checklist: refrigerate unopened stock if required; once opened keep below 25°C; discard after 4–6 weeks; store out of reach of children.
  • Single‑dose vials: use immediately after opening and discard any unused single‑use containers.
  • When travelling: follow cold‑chain advice for products that require refrigeration before opening; otherwise room temperature post‑opening is allowed within the product timeframe.
Condition Action
Before opening Refrigerate at 2–8°C if product label requires
After opening Store at room temperature below 25°C and protect from light
Discard Dispose after 4–6 weeks or as per manufacturer label

Guidelines for proper use

UK pharmacist counselling style

Patients commonly ask how to put the drop in without wasting it; demonstrating technique builds confidence and adherence.

Use patient‑centred, plain English instructions and demonstrate the instillation technique step‑by‑step.

NHS patient safety advice

  • Instillation technique: Tilt head back, pull down lower lid to form a pocket, instil one drop, close the eye gently for 1–2 minutes and apply nasolacrimal occlusion to reduce systemic absorption.
  • Contact lenses: Remove before instillation and wait ≥15 minutes before reinserting lenses.
  • Side effects: Discuss cosmetic side effects such as eyelash growth and iris pigmentation and ensure patients know when to seek help.
  • Monitoring milestones: Baseline IOP and optic nerve assessment, review at 4–6 weeks after initiation, then ongoing checks every 3–12 months depending on disease stability.

Delivery across the United Kingdom

City Region Delivery Time
London England 9–21 days
Birmingham England 9–21 days
Manchester England 9–21 days
Glasgow Scotland 9–21 days
Leeds England 9–21 days
Bristol England 9–21 days
Edinburgh Scotland 9–21 days
Liverpool England 9–21 days
Sheffield England 9–21 days
Newcastle Upon Tyne England 9–21 days
Belfast Northern Ireland 9–21 days
Cardiff Wales 9–21 days
Coventry England 9–21 days

Related products